Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2026-01-05 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于2025年度向特定对象发行股票申请获得中国证券监督管理委员会同意注册批复的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Sinocelltech Biotech Co., Ltd. regarding the approval from the China Securities Regulatory Commission (CSRC) for a specific private placement of shares in 2025. It includes details about the registration approval, conditions, and contact information for the issuer and sponsor. The content focuses on the company's capital raising activity through a private share issuance. The document length is short (835 characters) and it is clearly an announcement of a financing event rather than a detailed financial report or data. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-01-05 Chinese
神州细胞2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2025 second extraordinary shareholders meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the meeting date, attendance, voting results on various proposals including appointment of the 2025 audit firm, donation limits, amendments to company rules, and related party transactions. It also includes legal witness statements confirming the legality of the meeting and voting process. The content is focused on the official announcement of voting results from a shareholders meeting rather than the meeting materials or the full report itself. The document length is 3693 characters, which is relatively short and consistent with a voting results announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-12-29 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2025年第二次临时股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a legal opinion letter certifying the convening, attendance and voting procedures and, critically, detailing the vote counts and percentages for each resolution at the 2025 second extraordinary shareholders’ meeting. It serves as the formal declaration of voting results for that meeting, matching the definition for “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2025-12-29 Chinese
神州细胞自愿披露关于控股子公司产品新增适应症补充申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the approval of a supplementary application for a new indication of a product by its controlling subsidiary. It details the approval from the National Medical Products Administration for an additional use of a recombinant human coagulation factor VIII product. The document includes product details, regulatory approval information, and potential impact on the company. It is a regulatory announcement about product approval and does not contain financial statements, management discussion, or detailed financial data. It is not an annual report, earnings release, or any form of financial report. It is also not a report publication announcement or certification. The document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about product approval and related corporate information that does not fit other specific categories.
2025-12-25 Chinese
神州细胞关于获得政府补助的公告
Capital/Financing Update Classification · 90% confidence The document is a short announcement (447 characters) regarding the receipt of government subsidies by a company and includes a disclaimer about the accounting treatment and audit confirmation to come. It does not contain financial statements or detailed financial analysis. It is an update on financing-related activity (government grants) but not a full financial report or audit report. Given the nature of the announcement about government subsidies and its impact on the company, it fits best under Capital/Financing Update (CAP).
2025-12-25 Chinese
神州细胞2025年第二次临时股东会会议资料
AGM Information Classification · 100% confidence The document is titled as "2025 年第二次临时股东会会议资料" which translates to "2025 Second Extraordinary General Meeting (EGM) Meeting Materials". It contains detailed meeting instructions, agenda, and multiple proposals to be discussed and voted on at the shareholders meeting. The content includes procedural rules, voting methods, and detailed proposals such as appointment of auditors, donation limits, amendments to company policies, and capital increase in a subsidiary. The document is clearly a set of materials prepared for a shareholders meeting, not the announcement of voting results or the minutes of the meeting. It is not a full annual report, audit report, or earnings release. It is not a proxy solicitation or a voting results declaration. The document is a comprehensive set of meeting materials for a shareholders meeting, which fits the definition of AGM Information (AGM-R). The length and detail confirm it is the meeting materials themselves, not just an announcement or notice. Therefore, the correct classification is AGM Information (AGM-R).
2025-12-19 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.